MedPageToday -- SAN ANTONIO -- Almost half of women with early HER2-positive breast cancer had pathologic complete responses when treated preoperatively with the monoclonal antibodies pertuzumab and trastuzumab (Herceptin) plus chemotherapy, investigators reported here.
